Compare MDRR & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDRR | PRPH |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 6.0M |
| IPO Year | 2018 | 1997 |
| Metric | MDRR | PRPH |
|---|---|---|
| Price | $13.00 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.6K | ★ 3.6M |
| Earning Date | 11-06-2025 | 11-19-2025 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,098,461.00 | $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.83 | N/A |
| 52 Week Low | $9.55 | $0.11 |
| 52 Week High | $15.00 | $0.93 |
| Indicator | MDRR | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 26.02 |
| Support Level | $12.66 | $0.12 |
| Resistance Level | $13.62 | $0.16 |
| Average True Range (ATR) | 0.37 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 45.28 | 0.38 |
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.